Document › Details
Cellzome AG. (12/5/11). "Press Release: Cellzome Founder Wins EU Women Innovators Award. Dr. Gitte Neubauer Awarded First Prize for the Foundation of Cellzome". Heidelberg.
|Region||EU (European Union)|
|Group||GlaxoSmithKline (GSK) (Group)|
|Organisation 2||EMBL (Heidelberg, main laboratory)|
|Group||EMBL (European Molecular Biology Laboratory)|
|Product 2||Episphere™ technology|
|Person||Edwards, Tim (Cellzome 200507 CEO)|
Cellzome announces today that Dr. Gitte Neubauer, one of the scientific founders of Cellzome, has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome. The prize value of €100 000 awarded by the European Commission Innovation Union, was presented to Dr. Neubauer by the president of the European Commission, José Manuel Barroso in a ceremony as part of the Innovation Convention 2011 in Brussels.
Dr. Neubauer founded Cellzome together with a team of scientists and biotech veterans as a spin-out of the European Molecular Biology Laboratory in Heidelberg in 2000. She applied her experience and know-how in proteomics to build Cellzome's leading proteomics technology platform. More recently, she started the chemoproteomics-based assay development and screening group, to allow the efficient application of the technology to drug discovery. Today, Cellzome employs about 100 scientists and it applies its world-leading Kinobeads™ and Episphere™ technologies to the discovery of novel drug candidates to treat inflammatory diseases and cancer.
Receiving the award, Dr. Neubauer said: "I am very honoured to receive such a prestigious award and would like to thank the whole team of Cellzomers who have made the company so successful. It has been extremely rewarding to work with so many talented people over the years. I hope that the award is going to encourage more women to translate their research into innovation."
Tim Edwards, CEO of Cellzome and Chairman of the UK BioIndustry Association, congratulated Dr. Neubauer, saying: "My colleagues and I are delighted that Gitte Neubauer has won this award for her significant contribution in founding Cellzome and in playing a major role in the development of the Company over the past eleven years. Gitte has helped create Cellzome's chemoproteomics platform and led its development and integration into our drug discovery activities, a vital component of our collaborations with major pharmaceutical companies. Gitte is a great example to the many women we employ; hers is a great achievement."
Máire Geoghegan-Quinn, the Commissioner for Research, Innovation & Science of the EU said: "I warmly welcome the decision of the jury and would like to personally congratulate Dr. Neubauer for her outstanding achievements that are recognised by this award. Europe needs more women like her to serve as inspiration to young scientists, particularly young women. I am also very pleased that support from the EU's Framework Programme for Research has contributed to Dr. Neubauer's success."
- ends -
Cellzome AG Meyerhofstrasse 1, 69117 Heidelberg, Germany, Tel: +49 (0) 6221 137 57 0 Fax: +49 (0) 6221 137 57 201
Cellzome Limited Chesterford Research Park, Little Chesterford, Cambridge CB10 1XL, UK, Tel: +44 (0) 1799 532 800 Fax: +44 (0) 1799 532 801
About the EU Prize for Women Innovators
The EU Prize for Women Innovators is a pilot project of the European Commission. The competition was
designed to give public recognition to the outstanding women who brought their innovative products or
services successfully to the market and who where at some point in their careers beneficiaries of the
European Commission Framework Programme or Competitiveness and Innovation Programme. The awards
should at the same time boost public awareness of the contribution and potential of women researchers to
science and entrepreneurship and encourage women innovators to exploit the commercial and business
opportunities offered by their research projects to become themselves entrepreneurs.
Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology. The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world. Cellzome's technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases. The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis. Cellzome is a privately-held, international, company located in Heidelberg, Germany and Cambridge, UK employing about 100 people, of which 65% are women. For more information please visit: www.cellzome.com
About Dr. Gitte Neubauer
After graduating in Biochemistry at Imperial College, London with the highest marks of her year, Dr. Neubauer completed her PhD at the European Molecular Biology Laboratory working with Prof. Matthias Mann in the field of functional proteomics where she pioneered the mass spectrometric analysis of protein complexes. At Cellzome, she has been in charge of building and leading the mass spectrometry and IT departments before she was more recently made responsible for research operations and the setting up of the chemoproteomics screening facility. Dr. Neubauer is the author of 35 scientific publications, including 11 highly cited research articles (over 100 citations). She is a member of the advisory editorial board of the journal Drug Discovery Today, a Director of the Board of BioPro Baden-Württemberg, an agency providing advice and support to the life sciences sector and also a member of the industrial advisory board of the Biotechnology faculty of the University of Applied Sciences in Mannheim. Dr. Neubauer is married and has three children aged 7, 10 and 14 years.
For more information please contact:
Dr. Gitte Neubauer
Vice President Research Operations
Tel: +49 (0) 6221-137 57-100
Nicole Yost, Jayne Crook
Tel: +44 (0)20 7866 7862
Record changed: 2015-08-01
More documents for GlaxoSmithKline (GSK) (Group)
-  MorphoSys AG. (4/18/16). "Press Release: MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis"....
-  CureVac AG. (3/18/16). "Press Release: CureVac Strengthens Supervisory Board to Support Global Growth Opportunities and mRNA Product Expansion". Tübingen....
-  GlaxoSmithKline plc. (3/16/16). "Press Release: GSK and Miltenyi Biotec Establish Cell and Gene Therapy Collaboration"....
-  Medicxi Ventures. (2/3/16). "Press Release: Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210m Fund including GSK and Johnson & Johnson Innovation". Castres....
-  Novartis AG. (11/17/15). "Press Release: FLAME Study Shows Superiority of Novartis' Ultibro Breezhaler Over Seretide in Reducing COPD Exacerbations". Basel....
-  GlaxoSmithKline plc. (11/3/15). "Press Release: GSK Profiles Innovative R&D Portfolio to Investors. 40 Potential New Medicines and Vaccines". London....
-  Novartis AG. (10/27/15). "Press Release: Novartis Delivered Strong Core Margin Expansion (cc) and Continued to Strengthen the Pipeline in Q3, on Track for Full-year Guidance". Basel....
-  CureVac AG. (9/10/15). "Press Release: CureVac Establishes U.S. Operations in Cambridge, MA". Tübingen & Cambridge, MA....
-  LimmaTech Biologics AG. (8/28/15). "Press Release: LimmaTech Biologics AG Starts Operating"....
-  GlaxoSmithKline plc. (8/21/15). "Press Release: GSK to Divest Ofatumumab for Auto-immune Indications to Novartis for up to $1 Billion plus Royalties". London....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)